EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMetaanalyse

EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies

Pranati Dharmesh Shah, Sofia Yeremian, Emily Forte, Daniel Park, Emily Choi, Jerry Qi, Angel Nguyen, Mojtaba Akhtari

Journal of Investigative Medicine · 17.11.2026

DOI: 10.1177/10815589261507073 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Investigative Medicine, online erschienen am 17.11.2026. Verfasst von Pranati Dharmesh Shah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Loma Linda University Medical Center, Department of Medicine, Loma Linda, CA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies (BsAbs) are used for relapsed or refractory multiple myeloma (RRMM), but infectious complications remain an important concern. We estimated the reported proportion of all-grade and grade ≥3 infections during teclistamab, talquetamab, and elranatamab treatment. A systematic literature review was conducted with Pubmed to extract data which, included the number of patients, grade ≥ 3 infectious adverse events, and non-grade ≥ 3 infectious adverse events. Analyses were conducted using R software and the meta package. A random effect model was utilized. Eight studies (6 RCTs, 2 retrospective studies) involving 946 patients (teclistamab: 394, talquetamab: 374, elranatamab: 178) were analyzed. Pooled proportion (PP) for teclistamab was 0.517 [95% CI, 0.183–0.837], and grade ≥ 3 was 0.233 [95% CI, 0.058–0.598]. The talquetamab group had a PP of 0.636 [95% CI, 0.305–0.874], and grade ≥ 3 were 0.201 [95% CI, 0.110–0.339], with COVID-19 & pneumonia most reported. For elranatamab, the PP was 0.714 [95% CI, 0.397–0.904], with grade ≥ 3 infections at 0.344 [95% CI, 0.015–0.948]. Common infections were adenovirus, CMV, COVID-19, and pneumocystis jirovecii. Table 2 shows consistently reported AEs amongst the three bispecific antibodies for comparability. Infections were frequently reported, but substantial heterogeneity limits the precision and generalizability of a single pooled estimate. Consistent outcome definitions and follow-up are needed.

Schlagwörter

Stichwörter der Autor:innen

Bacterial InfectionsHematologic DiseasesViral Vaccines

Autor:innen und Institutionen

  • Loma Linda University Medical Center, Department of Medicine, Loma Linda, CA.
  • Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV.
  • University of California San Francisco, Fresno Campus, Department of Medicine, Fresno, CA.
  • Harbor UCLA, Department of Hematology Oncology, Torrance, CA.
  • Loma Linda University, School of Pharmacy, Loma Linda, CA.
  • University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Science, La Jolla, CA.

Zitieren

APA

Shah, P. D., Yeremian, S., Forte, E., Park, D., Choi, E., Qi, J., Nguyen, A., & Akhtari, M. (2026). EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies. Journal of Investigative Medicine. https://doi.org/10.1177/10815589261507073

Vancouver

Shah PD, Yeremian S, Forte E, Park D, Choi E, Qi J, et al. EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies. Journal of Investigative Medicine. 2026. doi:10.1177/10815589261507073

BibTeX
@article{Shah2026,
  author = {Shah, Pranati Dharmesh and Yeremian, Sofia and Forte, Emily and Park, Daniel and Choi, Emily and Qi, Jerry and Nguyen, Angel and Akhtari, Mojtaba},
  title = {EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies},
  journal = {Journal of Investigative Medicine},
  year = {2026},
  doi = {10.1177/10815589261507073}
}
Kostenlos starten →